Content by DDNews Staff

“A large number of pipeline agents with innovative approaches are under investigation for adjuvant, intermediate, and advanced therapy [for hepatocellular carcinoma].” Mandana Emamzadeh of GlobalData

Cell-based therapies could provide an advantageous alternative, but the development of these new therapies is often impaired and delayed by the lack of an appropriate model to test their safety and efficacy in humans before embarking in clinical trials.

Findings showed that Previse could predict the onset of AKI up to 48 hours in advance of onset, sooner than the standard hospital systems like XGBoost AKI prediction model and the Sequential Organ Failure Assessment (SOFA).

CKD is a slow and progressive loss of kidney function over several years, which can eventually cause permanent kidney failure. CKD often goes undetected and undiagnosed until the disease is well advanced, and the damage is irreversible resulting in poor survival rates. There are estimated to be 700 million cases of CKD worldwide, and currently there is no cure.

With a focus on comprehensive molecular disease classification, combined with prospective clinical outcomes, Chinook has the opportunity to potentially deliver targeted therapies to the right patient populations,” he added.

A look at some of the latest renal and hepatic R&D

“We have heard how difficult it has been to find standards and want to make it as easy as possible for the industry and suppliers to find the standards that can make product development and manufacturing processes more efficient.” Robert Shaw of SCB

“Beyond COVID-19, we believe SMAs have huge potential to unblock constrictions in the drug pipeline.”

“The COVID-19 pandemic could be an opportunity for the companies pursuing the development of gene therapies, as few products are in development to fight the viral illness.”
Alessio Brunello of GlobalData

Therapeutic candidates retain binding to major COVID-19-causing “South African” variant

ConserV Bioscience and eTheRNA immunotherapies collaborate on mRNA vaccines for infectious diseases

Pyxis Oncology closes $152-million Series B financing to further advance portfolio

New Mount Sinai study identifies a novel approach for tailored treatment that could be more effective for patients

Unique AI method developed at Chalmers for generating proteins could speed up drug development

Insilico and 2-control ApS join forces to create a solution to enhance biotech process development and production